Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 28 of 46

Summary: Nonbiologic and Biologic DMARDs Compared With Conventional Anti-inflammatory Treatment (2 of 2)

Overall, the evidence indicates that when compared with conventional treatment alone, adding methotrexate provides more consistent improvement in important outcomes as assessed by physicians, parents, and patients.
Strength of Evidence = Moderate

For patients who respond to a biologic DMARD after methotrexate treatment fails, the risk of a disease flare is reduced by half while treatment with the biologic DMARD continues (studies ranged from 2 months to 4 years).
Strength of Evidence = Moderate

Disease activity (symptoms) and health status improve with both classes of DMARDs, but the statistical significance of these effects is not known.
Strength of Evidence = Moderate